e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Novel treatments for cough, asthma, COPD and bronchiectasis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Evaluation of methotrexate in the treatment of severe asthma
Anita Molard (Strasbourg, France), François Hervy, Gairard-Dory Anne-Cécile, Anita Molard, Carine Metz-Favre, Cindy Barnig, Bénédicte Gourieux, Frédéric De Blay
Source:
International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Session:
Novel treatments for cough, asthma, COPD and bronchiectasis
Session type:
Thematic Poster Session
Number:
3956
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Anita Molard (Strasbourg, France), François Hervy, Gairard-Dory Anne-Cécile, Anita Molard, Carine Metz-Favre, Cindy Barnig, Bénédicte Gourieux, Frédéric De Blay. Evaluation of methotrexate in the treatment of severe asthma. Eur Respir J 2015; 46: Suppl. 59, 3956
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment?
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Asthma control, symptoms and exacerbations across treatment levels in patients with asthma
Source: Annual Congress 2013 –Management of respiratory diseases in primary care
Year: 2013
Combination therapy of ICSs/LABAs plus montelucastin patients with severe asthma
Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Year: 2015
Experience with omalizumab in patients with moderate and severe asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Predictors of exacerbations in asthma
Source: International Congress 2015 – Clinical assessment in asthma and COPD
Year: 2015
Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients
Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Year: 2016
Acute exacerbations of asthma in Barcelona, the recent experience
Source: Annual Congress 2013 –Epidemiology of asthma
Year: 2013
Use of beta-agonist therapy prior to hospital attendance for severe exacerbations of asthma
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy
Source: International Congress 2016 – Clinical and molecular studies in asthma
Year: 2016
Adherence to the treatment of patients with bronchial asthma
Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage?
Year: 2015
Sesonal variations of severe asthma exacerbations in the US
Source: International Congress 2014 – Risk factors for respiratory disease
Year: 2014
Effect of oral corticosteroids on symptomatic reflux in severe allergic asthma: Is there a link?
Source: International Congress 2014 – The assessment of comorbidities
Year: 2014
Clinical effectiveness of anti-IgE therapy in allergic severe asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Predictors of severe asthma exacerbations, poor asthma control and beta-agonist overuse in adult asthma
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Chronic oral corticosteroids use and persistent eosinophilia in severe asthma. The Belgian Severe Asthma Registry.
Source: Virtual Congress 2020 – Phenotypes of asthma and COPD
Year: 2020
Characterization of asthma exacerbations in outpatients – National survey
Source: International Congress 2015 – Clinical assessment in asthma and COPD
Year: 2015
Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Poor adherence to ICS treatment in patients with chronic respiratory diseases
Source: Annual Congress 2013 –Monitoring symptoms and quality of life
Year: 2013
Respiratory effectiveness group study: Predictors of frequent severe asthma exacerbations
Source: International Congress 2015 – Management of asthma and COPD in primary care
Year: 2015
LATE-BREAKING ABSTRACT: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept